# scientific reports



# **Ameliorative efects of sildenafl OPEN against carbon tetrachloride induced hepatic fbrosis in rat model through downregulation of osteopontin gene expression**

**Hend Elsayed Nasr1 , Ahmed Medhat Hegaz[y](http://orcid.org/0000-0001-8606-5937) <sup>2</sup>**\***, Noha Osama El‑Shaer3 , Rabab Shaban El‑shafey4 , SalwaA. Elgendy5 , HebaA. Elnoury5 , Walaa Bayoumie ElGazzar1 & LinaAbdelhady Mohammed1**

**The liver carries out many essential tasks, such as synthesising cholesterol, controlling the body's storage of glycogen, and detoxifying metabolites, in addition to performing, and regulating homeostasis. Hepatic fbrosis is a pathological state characterized by over accumulation of extracellular matrix (ECM) including collagen fbers. Sildenafl (a selective inhibitor of type 5 phosphodiesterase) has anti-infammatory, antioxidant and anti-apoptotic properties. It is commonly used to treat erectile dysfunction in male. The purpose of the current investigation was to evaluate sildenafl's hepatoprotective potential against liver fbrosis in rats that was caused by carbon tetrachloride (CCl4). Liver enzymes and oxidative markers as well as profbrotic genes were determined. The fndings showed that sildenafl alleviates the hepatic dysfunctions caused by CCl4 by restoring normal levels of ALT, AST, and GGT as well as by restoring the antioxidant status demonstrated by increased glutathione (GSH), and catalase. In addition, a signifcantly downregulated the mRNA expressions of profbrotic genes [collagen-1α, IL-1β, osteopontin (OPN), and transforming growth factor-β (TGF-β)]. Additionally, sildenafl lessens the periportal fbrosis between hepatic lobules, congestion and dilatation in the central vein, and the infammatory cell infltrations. As a result, it is hypothesized that sildenafl may be helpful in the management of hepatotoxicity**  brought on by CCl<sub>4</sub> through suppressing OPN.

**Keywords** Carbon tetrachloride, Hepatoprotective, Osteopontin, Oxidative markers, Sildenafl

The liver is a major organ in the body as it carries out a multitude of essential tasks, such as metabolite detoxifcation, cholesterol synthesis, and glycogen storage regulation, as well as body performance and homeostasis regulation<sup>1</sup>. Owing to its various metabolic functions, the liver is vulnerable to several illnesses. The major health problem is liver fbrosis which may lead to liver cirrhosis and liver cancer. A multifactorial process is driving chronic liver disease to cirrhosis<sup>[2](#page-8-1)</sup>. Hepatic fibrosis is a pathological state characterized by over accumulation of ECM including collagen fbers; it is a 'mis-repair' occurs in response to an infammatory reaction following chronic liver injury that resulting in activating hepatic stellate cells (HSCs) that considered the main source of myofibroblasts of the fibrotic liver<sup>3</sup>. These cells lead to degradation of the normal ECM of the liver, release of cytokines, and organ contraction<sup>[4](#page-8-3)</sup>. Liver fibrosis may be progressive and leads to cirrhosis. If the liver is not at the stage of advanced cirrhosis, the fbrotic response-causing agent can aid in the regression of fbrosis. Some of these cellular signals include morphogens, growth factors, and cytokines<sup>5</sup>. Osteopontin (OPN) is a highly phosphorylated glycoprotein, it was frst identifed in malignant cells; it was found in many tissues such as bile, milk, saliva,

<sup>1</sup>Department of Medical Biochemistery and Molecular Biology, Faculty of Medicine, Benha University, Benha 13518, Egypt. <sup>2</sup>Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Benha University, Moshtohor, Toukh 13736, Qalyubia, Egypt. <sup>3</sup>Department of Physiology, Faculty of Medicine, Benha University, Benha 13518, Egypt. <sup>4</sup>Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Benha University, Benha 13518, Egypt. <sup>5</sup>Deparment of Pharmacology, Faculty of Medicine, Benha University, Benha 13518, Egypt. <sup>⊠</sup>email: ahmed\_medhat012@yahoo.com; ahmed.hegazy@fvtm.bu.edu.eq

dentin layer of the tooth, brain, bone marrow, kidney, and liver[6](#page-8-5) . It considered as a signifcant chemical attractant for T cells and macrophages during inflammation<sup>7</sup>. Data reported that OPN gene is associated with the progression and pathogenesis of cancer, autoimmune, neurodegenerative, cardiovascular and renal diseases $^{\rm{s}}$ . Increased hepatic OPN expression was accompanied with fbrosis in patients with HBV and HCV infection, schistosomiasis mansoni, alcoholic liver diseases and as a marker for the conversion of liver fbrosis to cirrhosis. It also served as a diagnostic marker of portal hypertension and HCC<sup>9</sup>. OPN exists in a secreted form that mediates cell adhesion, migration and survival, and an intracellular non-secreted form. During hepatic fbrogenesis, activation of quiescent HSCs is promoted by OPN then subsequently increases the expression and secretion of collagen-1[10](#page-8-9).

Sildenafl, a phosphodiesterase-5 inhibitor, has anti-apoptotic, antioxidant and anti-infammatory properties, and improve the immune system function; it decreases oxidative stress in brain and kidneys of rats with cisplatin or ischemia that induced acute kidney injury (AKI) and diabetic nephropathy<sup>11</sup>. The drug ameliorated smokeinduced lung inflammation, and inflammatory demyelination in rats $12$ . Thus, the purpose of this study was to assess sildenafil's hepatoprotective effects against liver fibrosis in wistar rats caused by CCl<sub>4</sub>.

#### **Materials and methods Ethical approval**

The Institutional Animal Ethics Committee at Benha University in Egypt provided instructions and procedures that were followed during the conduct of this experiment. The protocol number for approval is BUFVTM 09-11-22. All methods were performed in accordance with the relevant guidelines and regulations. The study is reported in accordance with ARRIVE guidelines.

# **Chemicals**

Sildenafil (Viagra<sup>\*</sup>) (100 mg/tablet) was purchased from Pfizer Co., Egypt. The carbon tetrachloride (CCl<sub>4</sub>) was purchased from NICE Co., India.

# **Experimental animals**

At six weeks of age and weighing between 125 and 145 g, forty adult male Wistar rats were procured from the animal house of the National Research Centre in Egypt (Dokky, Giza, Egypt). The rats were provided with free, clean water, a balanced diet, and a clean environment in which to live. The rats were housed in a natural 12 h light/dark cycle with an ambient temperature of  $23 \pm 3$  °C. Rats were burned in an incinerator following the completion of the experiment and sample collection.

# **Experimental design**

Four equal groups of ten rats each were randomly assigned to the experimental rats. The group 1 (G1) was preserved as a normal control, and the group 2 (G2) was administered orally sildenafl dissolved in saline by stomach tube at a dose of 20 mg/kg b.wt.<sup>13</sup>. daily for 4 weeks. The group 3 (G3) (intoxicated group) was administered intraperitoneal (I/P) CCl<sub>4</sub> (30% in olive oil) at a dose of 3 mg/kg b.wt <sup>14</sup>. twice a week for 4 weeks. Group 4 (G4), which received co-treatment, received sildenafil via stomach tube at a dose of 20 mg/kg b.wt. daily and CCl<sub>4</sub> I/P at a dose of 3 mg/kg b.wt. twice a week for 4 weeks. Throughout the experiment, all groups' clinical symptoms were noted. At the end of the experiment, the experimental rats were euthanized using isofurane inhalation. Blood for serum samples was collected from the abdominal aorta, and liver specimens were collected from all rats in each group at the end of the fourth week of the experiment for evaluation of liver function, oxidative markers, gene expression, histopathological changes, and immunohistochemically markers.

# **Preparation of liver homogenate**

The liver tissue homogenate was made in compliance with Farid and Hegazy<sup>15</sup>. The total protein and the oxidative indicators [catalase (CAT), reduced glutathione (GSH), and lipid peroxidation by-products (MDA) level] were measured in the obtained supernatant.

# **Assay methods**

#### *Liver function tests*

The activity of alanine aminotransferase  $(ALT)^{16}$  $(ALT)^{16}$  $(ALT)^{16}$ , aspartate aminotransferase  $(AST)^{16}$ , and gamma glutamyltransferase  $(GGT)^{17}$  were performed.

# *Oxidative markers in liver homogenate*

The levels of  $MDA^{18}$ , GSH<sup>19</sup>, CAT<sup>20</sup>, and the total proteins content<sup>[21](#page-8-20)</sup> were performed in the liver homogenates.

#### *Hepatic mRNA gene expression*

The mRNA expression of hepatic collagen-1α, interleukin-1β (IL-1β), osteopontin (OPN), and TGF-β genes were analyzed using a 7300 real-time PCR system (PCR) (Applied Biosystems, Foster City, CA, USA). Te expression of hepatic collagen-1α, IL-1β, OPN, and TGF-β cytokines and β-actin (as a housekeeping gene) were analyzed with sense and antisense primers according to a previously published method<sup>[22](#page-8-21)</sup> used the primers sets (Table [1\)](#page-2-0). The changes in gene expression were estimated from the obtained cycle threshold (Ct) values provided by the real-time PCR equipment using the comparative Ct method to a reference (β-actin, housekeeping gene)<sup>[23](#page-8-22)</sup>.

2



<span id="page-2-0"></span>Table 1. The primer sets of the assessed genes.

#### *Histopathological examinations*

Tissue specimens from liver of each rat were collected immediately afer euthanized, rinsed with isotonic saline, and fxed in 10% neutral bufered formalin and dehydrated by serial ethanol solutions (70, 95, and 100%, respectively). Parafn-embedded tissue sections (~5 μm thickness), and stained with hematoxylin and eosin (H&E) and with Masson's trichrome<sup>[24](#page-8-23)</sup>. For a histopathological assessment, the slides were inspected using a light microscope (Olympus BX50, Japan).

#### *Immunohistochemistry staining*

The liver slices  $(5 \mu m)$  were adhered to glass microscope slides with positive charge. Sections deparaffinized and then rehydrated with decreasing alcohol concentration. For thirty minutes, a microwave was used to heatinduced antigen retrieval using a citrate bufer solution. Afer allowing the sections to cool at room temperature, nonspecifc binding was stopped for 20 min at that temperature using regular goat serum. Incubation with the diluted primary antibodies [alpha-smooth muscle actin (α-SMA) Monoclonal Antibody, Catalog # 14-9760-82, Thermo Fisher Scientific, Manor Park, United Kingdom] at a dilution rate of 1:200 for 60 min at 37 ℃. After that, sections were exposed to a peroxidase suppressor for 15 min at room temperature in order to inhibit the activity of endogenous peroxidase. Subsequently, the DAB chromogen mixture was applied to each slide afer they had been incubated for one hour at room temperature with the secondary antibody (goat anti-rat peroxidase conjugated streptavidin). PBS was used for washing and drying afer each step. To show the nuclei, sections were counter-stained with Meyer's hematoxylin. A dark brown response indicated good immuno-expression. Except for adding the primary antibodies, a negative control underwent the previously described procedures<sup>25</sup>.

#### *Image analysis*

Using an Olympus CX51 microscope, the percentage of the area (area %) covered by the blue color in the Masson's trichrome staining or immunostaining area for α-SMA was examined, and photos were captured with an Olympus digital camera (E-620, United States). Digital image analysis was used to evaluate and quantify the images using the computer programme Scion Image Beta 4.03 (Scion Corporation, USA).

#### **Statistical analysis**

The information was shown as mean ± standard deviation (SD). ANOVA was used to determine the significance of mean diferences, and Duncan's multiple range test was then performed using SPSS for Windows (version 20.0; SPSS Inc., Chicago, Ill.). The difference of means at  $P < 0.05$  is considered significant.

#### **Consent to participate**

Acceptance of participation, each individual participant in this study provided both oral and written informed permission.

#### **Results**

No any symptoms or rat died in any of the experimental groups over the course of the experiment.

#### **Liver function tests**

Afer the fourth week of treatment, the CCl4-treated group's levels of ALT, AST, and GGT considerably increased in comparison to the other experimental groups. However, following the fourth week of the trial, ALT, AST, and GGT levels were mitigated in the group that received sildenafil and  $\text{CCl}_4$  (Table [2](#page-3-0)).

#### **Changes in the liver oxidative markers**

When compared to the other experimental groups, the CCl<sub>4</sub>-treated group's liver tissue exhibited considerably lower GSH contents and lower CAT activities. However, following the fourth week of the trial, the group that received both sildenafil and CCl<sub>4</sub> co-treatment exhibited alleviation of these activities. When compared to the other experimental groups, the CCl<sub>4</sub>-treated group's levels of MDA, a marker of LPO in liver tissue, were also signifcantly higher; however, afer the fourth week of the experiment, the group that received both sildenafl and CCl<sub>4</sub> co-treatment showed mitigation of MDA levels (Table [3\)](#page-3-1).



<span id="page-3-0"></span>**Table 2.** Effect of sildenafil against carbon tetrachloride (CCl<sub>4</sub>) on liver function test in various gatherings of the experiment after 4 weeks of treatment (mean  $\pm$  standard deviation), ( $n=10$ ). Means with different superscripts in the same row are significantly different at  $P < 0.05$ .



<span id="page-3-1"></span>**Table 3.** Effect of sildenafil against carbon tetrachloride (CCl<sub>4</sub>) on oxidative markers in the liver homogenates of various gatherings of the experiment afer 4 weeks of treatment (mean±standard deviation), (*n*=10). Means with different superscripts in the same row are significantly different at *P*<0.05.

#### **Collagen‑1α, IL‑1β, OPN, and TGF‑β mRNA expression in liver tissue**

Figure [1](#page-3-2) shows the expression of mRNA genes for liver collagen-1α, IL-1β, OPN, and TGF-β in the control group and groups treated with sildenafil, CCl<sub>4</sub>, and sildenafil+CCl<sub>4</sub> after four weeks of treatment. The liver mRNA of the rats treated with CCl<sub>4</sub> showed a significant elevation of collagen-1α, IL-1β, OPN, and TGF-β. Conversely, there was a noticeable downregulation of these genes in the group that received sildenafil and CCl<sub>4</sub> together.



<span id="page-3-2"></span>from hepatic tissues of rats treated with sildenafil, CCl<sub>4</sub>, sildenafil against CCl<sub>4</sub>, and control on 4 weeks after treatments. Real-time PCR was evaluated the expression levels. *P* ˂ 0.05 compared with control values. Bars represent means  $\pm$  SDM. ( $n=10$ ).

4

### **Histopathological assessment of liver tissue**

Examination of liver sections stained with H and E revealed that  $CCl<sub>4</sub>$  treated rats showed sever degenerative changes with distorted histological architecture, vacuolization (circle), sever congested central vein (CV), congested portal tract vasculature (PT), large infammatory cells infltrates (asterisk), some congested sinusoids (arrow), and other dilated sinusoids (angled arrow) were seen (Fig. [2B](#page-4-0), [C\)](#page-4-0). Treatment of rats with sildenafl and CCl<sub>4</sub> showed improvement of the hepatic architecture but mild congestions between the hepatocytes were still noticed (Fig. [2D](#page-4-0)). The hepatic tissues of rats that administered sildenafil appeared to be normal (Fig. [2](#page-4-0)A).

#### **Masson's trichrome stain examination**

Examination of liver sections stained with Masson's trichrome showed that rats received CCl<sub>4</sub> displayed a significant increase in the amount of collagen fber deposition in the portal area and around the central veins (Fig. [3B](#page-5-0), [C\)](#page-5-0). The Masson's trichrome area (%) was markedly increased in the CCl<sub>4</sub> treated group (G3) after 4 weeks of experiment (Fig. [3E](#page-5-0)). On the other hand, treatment of rats with sildenafil and CCl<sub>4</sub> showed reduced collagen fiber deposition (Fig. [3D](#page-5-0)). The Masson's trichrome area (%) was markedly decreased when rats treated with sildenafil and CCl<sub>4</sub> after 4 weeks of experiment (Fig. [3E](#page-5-0)). The minimal collagen expression just around the central veins were detected in the control, and sildenafl-treated groups (Fig. [3A](#page-5-0)).

#### **Immunohistochemical assessment of liver tissue**

Α-smooth muscle actin (α-SMA) immunohistochemical staining sections of liver tissues observed that rats exposed to CCl4 revealed that α-SMA protein is highly expressed in the area of central vein, portal tract, and between hepatocytes indicating fibrotic changes (Fig. [4C](#page-6-0)). The α-SMA area (%) was markedly increased in the CCl4 treated group (G3) afer 4 weeks of experiment (Fig. [4](#page-6-0)E). While rats treated with sildenafl and CCl4 showed mild  $\alpha$ -SMA-expression, and the level of positivity is lower than in the CCl<sub>[4](#page-6-0)</sub> treated rats (Fig. 4D). The  $\alpha$ -SMA area (%) was markedly decreased in the sildenafil and CCl<sub>4</sub> treated group (G4) after 4 weeks of experiment (Fig. [4](#page-6-0)E). The α-SMA immunohistochemical staining sections of liver tissues of normal control, and sildenafiltreated rats showed a minimal reaction in the vascular wall (Fig. [4A](#page-6-0), [B](#page-6-0)).



<span id="page-4-0"></span>**Figure 2.** Liver sections of rats from different experimental groups. (**A**) The control group (G1) and (G2) received sildenafl and showed a normal histological features of the liver with no abnormalities. Cords of hepatocytes (H) radiating from the central vein (CV). (**B**,**C**) show liver of G3 rats that received CCl4. (**B**) Shows sever degenerative changes with distorted histological architecture, vacuolization (circle), congested portal tract vasculature (PT), large infammatory cells infltrates (asterisk), and congested sinusoids (arrow). (**C**) Shows Sever congested central vein (cv), dilated sinusoids (angled arrow), and large infammatory cells infiltrates (asterisk). (D) G4 received sildenafil and CCl<sub>4</sub> and showed improvement of hepatic architecture with congestions between some hepatocytes (H&E×100).



<span id="page-5-0"></span>**Figure 3.** Liver sections of rats from different experimental groups stained with Masson's trichrome. (A) The control group (G1) and (G2) received sildenafl and showed minimal collagen expression just around the central veins. (B,C) Show liver of G3 rats that received CCl<sub>4</sub>; showed increased collagen fibers deposition in the portal area and around the central veins. (D) G4 received sildenafil and CCl<sub>4</sub> and showed reduced collagen deposition compared to G3 group. (Masson's trichrome×100). (**E**) Show digital morphometric study of area (%) of Masson's trichrome of liver of experimental rats. Data were used to estimate the degree of Masson's trichrome stain. *P*<0.05 compared with different experimental groups. Bars represent mean  $\pm$  SDM. (*n* = 10).

# **Discussion**

The purpose of this study was to investigate if sildenafil could adequately support liver function in Wistar rats given CCl4 to induce liver fbrosis. Chronic liver diseases causes health problem with high morbidity and mortality rates all over the world<sup>26</sup>. Liver fibrosis, which is defined by an imbalance between excessive matrix synthesis and matrix breakdown, is the result of persistent tissue injury-induced defective wound healing<sup>27</sup>. It has been determined that HSCs are the primary cells that produce matrix along the course of liver fibrosis<sup>[28](#page-8-27)</sup>. Multiple cell types of hepatic progenitor cells are involved in the process of liver repair; the HSCs or liver pericytes, and liver progenitor cells (LPCs) or oval cells are the most important cells involved in this process<sup>[29](#page-8-28)</sup>. Chronic liver injury results in sustained activation of quiescent HSCs (qHPCs) which is transformed into active HPCs (aHPCs) or myofibroblasts, which secrete collagen into the ECM<sup>30</sup>. Furthermore, LPCs are reprogrammed into fiber secreting



<span id="page-6-0"></span>**Figure 4.** Immunohistochemical expression of α-smooth muscle actin (α-SMA) in liver tissue from diferent experimental groups. The brown color indicating positivity. (A) The control group (G1) showed slight amount of α-SMA-positivity merely seen in vascular wall. (**B**) G2 received sildenafl showed no diference compared with control. (**C**) G3 rats that received CCl4 showed the α-SMA protein is highly expressed in the area of central vein, portal tract, and between hepatocytes. (**D**) G4 received sildenafil and CCl<sub>4</sub> and showed mild α-SMA-expression; however, the level of positivity is lower than in the G3. (Anti-α-SMA immunostaining×100). (**E**) Digital morphometric study of area (%) of α-SMA immunohistochemical staining sections of liver of experimental rats. Data were used to estimate the degree of α-SMA immunohistochemical staining. *P*<0.05 compared with diferent experimental groups. Bars represent mean±SDM. (*n*=10).

cells (epithelial to mesenchymal transition) and recruited immune cells (efector–profbrogenic) amplify the process of fibrogenic deposition<sup>31</sup>.

The current study revealed that the activity of ALT, AST and GGT markedly increased that indicated damage of the hepatic tissue of CCl<sub>4</sub>-treated group after 4 weeks administration. This could be the result of inflammation and hepatocellular damage, which raises the permeability of the cell membrane and releases transaminases into the blood stream. A similar results were recorded in rats treated with  $CCl_4^{32}$  $CCl_4^{32}$  $CCl_4^{32}$ . GGT activity increase is linked to all types of primary and secondary hepatobiliary diseases; higher blood levels of GGT are associated with cholestasis brought on by intrahepatic or extrahepatic biliary blockage[33](#page-8-32). Marked decreases in serum ALT, AST, and GGT levels in rats co-treated with sildenafil+ CCl<sub>4</sub> were recorded. The hepatoprotective activity may be attributed to

7

an anti-inflammatory property of sildenafil. These findings coincided with Molehin et al.<sup>34</sup> who found that the sildenafil moderately reduced hepatotoxicity of CCl<sub>4</sub>.

In this work, rats treated with CCl4 showed decreased GSH contents and CAT activity afer the fourth week of therapy, and an increase in LPO as evidenced by an elevation in MDA levels. This effect may have resulted from damage to cellular components and peroxidation of membrane lipids<sup>35</sup>. The primary mechanism of CCl<sub>4</sub>-induced liver damage is oxidative stress, whereby hepatic cytochrome P450 metabolizes CCl<sub>4</sub> to produce the trichloromethyl radical; promote hepatocyte necrosis, impair liver functioning, and upset hepatic architecture as a result of free radicals produced by CCl<sub>4</sub> induction<sup>36</sup>. The reactive oxygen species (ROS) which deplete endogenous antioxidants and interact with cellular lipids leading to lipid-peroxidation<sup>36</sup>. Rats co-treated with sildenafil and CCl4 showed decreased LPO (MDA) levels and increased GSH content and CAT activity. Tese fndings corroborate those of Abd El Motteleb et al.[37,](#page-9-2) who discovered that sildenafl protects against oxidative stress and liver impairment brought on by bile duct ligation. Sildenafl depresses the generation of hydrogen peroxide by inducing the activity of antioxidants and preventing ROS generation. Tus, sildenafl improved the antioxidants concentrations and reduced oxidative stress. The GSH is the most important cellular antioxidant that plays an important role in scavenging of free radical $s^{38}$ .

In the present study, there was statistically signifcant upregulation of hepatic collagen-1α, IL-1β, OPN, and TGF-β mRNA expression when rats treated with CCl<sub>4</sub> after the fourth week of the experiment. Collagen-1α, IL-1β, OPN, and TGF-β mRNA expression were all shown to be downregulated in rats given sildenafl and CCl<sub>4</sub>. These findings agree with Kaleta et al.<sup>[39](#page-9-4)</sup>. Sildenafil caused suppressive effects on many pro-inflammatory cytokines through its efect on oxidative and infammatory pathways and the overexpression of pro-infammatory cytokines, such as IL-1β, was reduced by sildenafl; these cytokines have synergistic efects that stimulate immune and non-immune cells, as well as other cytokines and adhesion molecules<sup>[40](#page-9-5)</sup>.

The CCl<sub>4</sub>-treated rats significantly increased the expression of OPN. These findings corroborate those of Kaleta et al.<sup>41</sup>. Hepatic OPN expression correlated with inflammatory cell infiltration in the portal area; during CCl4 intoxication, OPN facilitated the accumulation of macrophages at sites of injury and consequently enhance hepatic inflammation, hepatic stellate cells, and fibrogenesis<sup>42</sup>. Phosphodiesterase inhibitors elevate cGMP level, which inhibits fibroblast-to-myofibroblast transition that represent an important source of osteopontin<sup>[43](#page-9-8)</sup>. Moreo-ver, Kaleta et al.<sup>[39](#page-9-4)</sup> demonstrated that sildenafil downregulates OPN gene expression in human peripheral mononuclear cells; that secret OPN during chronic liver injury as patients with primary biliary cirrhosis, autoimmune hepatitis, hepatic cirrhosis, and primary sclerosing cholangitis have all been shown to have elevated hepatic OPN levels. Sildenafl downregulates OPN gene expression, this may refer to the immunomodulatory and anti-inflammatory effects of sildenafil on human immune system cells<sup>[44](#page-9-9)</sup>. Numerous cell types express OPN during the hepatic fbrotic healing process. Hepatocytes and immune cells (macrophages, Kupfer cells) express more OPN mRNA, and OPN also attracts more neutrophils and macrophages to the area. Moreover, hepatic progenitor cells like HSC express OPN signifcantly while transitioned from Q-HSC to become MF-HSC then OPN stimulate the migration of hepatic progenitor cells towards the site of necrosis in the liver. It has been demonstrated that OPN stimulates HSC migration, proliferation, and epithelial-mesenchymal transition; it also produces factors that activate nearby progenitor cells and cells that produce ECM. It contributes to liver tissue scarring in both an autocrine and paracrine manner<sup>45</sup>.

The CCl<sub>4</sub>-treated rats significantly increased the expression of hepatic collagen-1α and TGF-β. While cotreated with sildenafil + CCl<sub>4</sub> showed down regulation of these genes. These findings corroborate those of Abd El Motteleb et al.<sup>37</sup>. A profibrogenic reaction was set off by damaged liver cells, which increased TGF-β expression and transformed latent TGF-β into active form, which activated HSCs. Higher hepatic expression of collagen-1α indicates upregulation of TGF-β gene content linked to HSC activation. TGF-β1 phosphorylates Smad2/3 proteins via activating its own receptors on HSCs. Increased production of collagen-1α is caused by phosphorylated Smad2/3 protein translocating into the nucleus and forming a complex with Smad4. One important cytokine that has been identifed as mediating liver fbrosis is TGF-[β46.](#page-9-11) Activated HSCs promote the migration and proliferation of myogenic markers, such as α-SMA, transforming them into the primary cells that produce collagen-1α; the primary constituent of the ECM that accumulates and plays a crucial role in the onset and progression of liver fibrosis<sup>47</sup>. The group that received sildenafil and CCl<sub>4</sub> had lower levels of hepatic TGF-β and collagen-1α gene expression; these findings are consistent with those reported by Xiang et al.<sup>48</sup>. The potential reason for sildenafil's antifibrotic impact could be its ability to inactivate HSC through the inhibition of TGF- $\beta$  production<sup>[49](#page-9-14)</sup>.

The improvement in  $\alpha$ -SMA immunohistochemistry characteristics of the liver of rats treated with CCl<sub>4</sub> was corroborated by these data; revealed that α-SMA protein is highly expressed in the area of central vein, portal tract, and between hepatocytes indicating fibrotic changes<sup>[50](#page-9-15)</sup>. While rats treated with sildenafil and CCl<sub>4</sub> showed mild  $\alpha$ -SMA-expression.  $\alpha$ -SMA is frequently employed as a diagnostic tool for the initial phases of fibrosis<sup>51</sup>.

These findings were consistent with the improvement in the liver's histological characteristics of sildenafiltreated rats compared with the liver of CCl4-treated rats, which showed sever degenerative changes, vacuolization, sever congested central vein, congested portal tract vasculature, large infammatory cells infltrates, in addition to congested and dilated sinusoids. The outcomes aligned with the results of an earlier investigation<sup>37</sup> that used bile duct ligation to cause liver fibrosis and sildenafil co-treatment. These findings were also corroborated by those of the Masson's trichrome stain examination. It revealed the improvement of collagen fber deposition in the portal area and around the central veins in rats treated with sildenafil and CCl<sub>4</sub>. These results aligned with those of an earlier investigation<sup>[52](#page-9-17)</sup> that induced liver fibrosis in rats by CCl<sub>4</sub> and co-treated with Zataria multiflora Boiss essential oil.

# **Conclusion**

Oxidative stress and profbrotic genes (OPN and TGF-β) played pivotal role in chronic liver diseases. Modulation of oxidative stress and suppression of profbrotic genes by sildenafl decreased hepatic progenitor response and protected the liver against fbrosis. Tus, sildenafl is a potentially attractive anti-fbrotic strategy in the liver fbrosis.

# **Data availability**

The corresponding author will deliver the information needed to back up this study's conclusions upon reasonable request and with permission from the Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Benha University. The protocol number for approval is: BUFVTM 09-11-22.

Received: 6 June 2024; Accepted: 10 July 2024 Published online: 23 July 2024

#### **References**

- <span id="page-8-0"></span>1. Zhao, T. *et al.* Regulating Nrf2-GPx4 axis by bicyclol can prevent ferroptosis in carbon tetrachloride-induced acute liver injury in mice. *Cell Death Discov.* **8**(1), 380 (2022).
- <span id="page-8-1"></span>2. Long, X. *et al.* Preventive efect of *Lactobacillus plantarum* HFY15 on carbon tetrachloride (CCl4)-induced acute liver injury in mice. *J. Food Sci.* **87**(6), 2626–2639 (2022).
- <span id="page-8-2"></span>3. Zhang, X. *et al.* Targeting hepatic stellate cell death to reverse hepatic fbrosis. *Curr. Drug Targets* **24**(7), 568–583 (2023).
- <span id="page-8-3"></span>4. Nianan, L., Jiangbin, L., Yu, W., Jianguo, L. & Rui, D. Hepatic stellate cell: A double-edged sword in the liver. *Physiol. Res.* **70**(6), 821 (2021).
- <span id="page-8-4"></span>5. Zhao, T. *et al.* Efect of ADHI on hepatic stellate cell activation and liver fbrosis in mice. *Biochem. Biophys. Res. Commun.* **651**, 98–106 (2023).
- <span id="page-8-5"></span>6. Xu, C., Wu, Y. & Liu, N. Osteopontin in autoimmune disorders: Current knowledge and future perspective. *Infammopharmacology* **30**(2), 385–396 (2022).
- <span id="page-8-6"></span>7. Leung, L. L., Myles, T. & Morser, J. Trombin cleavage of osteopontin and the host anti-tumor immune response. *Cancers* **15**(13), 3480 (2023).
- <span id="page-8-7"></span>8. Bastos, A. C. S. D. F. *et al.* The intracellular and secreted sides of osteopontin and their putative physiopathological roles. *Int. J. Mol. Sci.* **24**(3), 2942 (2023).
- <span id="page-8-8"></span>9. Sheiko, A. & Yurko, K. Te value of osteopontin in predicting fbrosis in patients with chronic viral hepatitis C. *Gastroenterology* **57**(3), 166–171 (2023).
- <span id="page-8-9"></span>10. Ramadan, A. *et al. Mesalazine*, an osteopontin inhibitor: The potential prophylactic and remedial roles in induced liver fibrosis in rats. *Chem. Biol. Interact.* **289**, 109–118 (2018).
- <span id="page-8-10"></span>11. El-Tanbouly, G. S. & Khalil, R. Novel therapeutic approaches of sildenafl against rhabdomyolysis-associated acute kidney injury. *J. Adv. Pharm. Res.* **6**(3), 144–154 (2022).
- <span id="page-8-11"></span>12. Ren, Z. et al. Therapeutic sildenafil inhibits pulmonary damage induced by cigarette smoke exposure and bacterial inhalation in rats. *Pharm. Biol.* **58**(1), 116–123 (2020).
- <span id="page-8-12"></span>13. El Motteleb, D. M. A., Ibrahim, I.A.-H. & Elshazly, S. M. Sildenafl protects against bile duct ligation induced hepatic fbrosis in rats: Potential role for silent information regulator 1 (SIRT1). *Toxicol. Appl. Pharmacol.* **335**, 64–71 (2017).
- <span id="page-8-13"></span>14. Khan, R. A., Khan, M. R. & Sahreen, S. CCl4-induced hepatotoxicity: Protective efect of rutin on p53, CYP2E1 and the antioxidative status in rat. *BMC Complement. Altern. Med.* **12**(1), 1–6 (2012).
- <span id="page-8-14"></span>15. Farid, A. S. & Hegazy, A. M. Ameliorative efects of *Moringa oleifera* leaf extract on levofoxacin-induced hepatic toxicity in rats. *Drug Chem. Toxicol.* **43**(6), 616–622 (2020).
- <span id="page-8-15"></span>16. Reitman, S. & Frankel, S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am. J. Clin. Pathol.* **28**(1), 56–63 (1957).
- <span id="page-8-16"></span>17. Rosalki, S. B. & Rau, D. Serum γ-glutamyl transpeptidase activity in alcoholism. *Clin. Chim. Acta* **39**(1), 41–47 (1972).
- <span id="page-8-17"></span>18. Ohkawa, H., Ohishi, N. & Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal. Biochem.* **95**(2), 351–358 (1979).
- <span id="page-8-18"></span>19. Ellman, G. L. Tissue sulfydryl groups. *Arch. Biochem. Biophys.* **82**(1), 70–77 (1959).
- <span id="page-8-19"></span>20. Luck, H. Spectrophotometric method for the estimation of catalase. In *Methods of Enzymatic Analysis* (ed. Bergmeyer, H. U.) 886–887 (New York Academic press, 1963).
- <span id="page-8-20"></span>21. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**, 265–275 (1951).
- <span id="page-8-21"></span>22. Farid, A. S., Mido, S., Linh, B. K., Hayashi, T. & Horii, Y. An atherogenic lipid profle with low serum paraoxonase-1 activity during nematode infection in rats. *Eur. J. Clin. Investig.* **40**(11), 984–993 (2010).
- <span id="page-8-22"></span>23. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C T method. *Nat. Protoc.* **3**(6), 1101 (2008).
- <span id="page-8-23"></span>24. Suvarna, K. S., Layton, C. & Bancroft, J. D. *Bancroft's theory and practice of histological techniques E-Book* (Elsevier Health Sciences, 2018).
- <span id="page-8-24"></span>25. Suvarna, K. S., Layton, C. & Bancrof, J. Immunohistochemical techniques. In *Bancrof's Teory and Practice of Histological Techniques* 7th edn 387–418 (Churchill Livingstone Elsevier, 2013).
- <span id="page-8-25"></span>26. Ani, K., Marina, S., Norah, T. & Lauren, N. Health disparities in chronic liver disease. *Hepatology* **77**(4), 1382–1403 (2023).
- <span id="page-8-26"></span>27. Melnik, B. C., Weiskirchen, R., Stremmel, W., John, S. M. & Schmitz, G. Narrative review of bovine milk exosomes as a potential therapeutic option for hepatic fbrosis. *Digest. Med. Res.* **5**, 14 (2022).
- <span id="page-8-27"></span>28. Acharya, P., Chouhan, K., Weiskirchen, S. & Weiskirchen, R. Cellular mechanisms of liver fbrosis. *Front. Pharmacol.* **12**, 671640 (2021).
- <span id="page-8-28"></span>29. Lucantoni, F. *et al.* Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fbrosis: Are we there yet?. *J. Pathol.* **254**(3), 216–228 (2021).
- <span id="page-8-29"></span>30. Zhou, L. *et al.* Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fbrosis therapy. *Acta Biomater.* **152**, 235–254 (2022).
- <span id="page-8-30"></span>31. Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fbrosis and its regression. *Nat. Rev. Gastroenterol. Hepatol.* **18**(3), 151–166 (2021).
- <span id="page-8-31"></span>32. Atta, A. H. *et al.* Phytochemical, antioxidant and hepatoprotective efects of diferent fractions of *Moringa oleifera* leaves methanol extract against liver injury in animal model. *Asian Pac. J. Trop. Med.* **11**(7), 423 (2018).
- <span id="page-8-32"></span>33. Lala, V., Zubair, M., Minter, D. Liver function tests. StatPearls.<https://www.statpearls.com/point-of-care/20995/> (2023).
- <span id="page-8-33"></span>34. Molehin, O. R. *et al.* Sildenafl, a phosphodiesterase-5 inhibitor, ofers protection against carbon tetrachloride-induced hepatotoxicity in rat. *J. Basic Clin. Physiol. Pharmacol.* **29**(1), 29–35 (2018).
- <span id="page-9-0"></span>35. Lamia, S. S. *et al.* Coenzyme Q10 and silymarin reduce CCl4-induced oxidative stress and liver and kidney injury in ovariectomized rats—Implications for protective therapy in chronic liver and kidney diseases. *Pathophysiology* **28**(1), 50–63 (2021).
- <span id="page-9-1"></span>36. Atta, A. H. *et al.* Hepatoprotective and antioxidant efects of methanol extractof *Moringa oleifera* leaves in rats. *Wulfenia J.* **24**(3), 249–268 (2017).
- <span id="page-9-2"></span>37. Abd El Motteleb, D. M., Ibrahim, I. A. H. & Elshazly, S. M. Sildenafl protects against bile duct ligation induced hepatic fbrosis in rats: Potential role for silent information regulator 1 (SIRT1). *Toxicol. Appl. Pharmacol.* **335**, 64–71 (2017).
- <span id="page-9-3"></span>38. Chhonker, S. K., Rawat, D. & Koiri, R. K. Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma. *Mol. Cell. Biochem.* **476**, 1195–1209 (2021).
- <span id="page-9-4"></span>39. Kaleta, B. & Boguska, A. Sildenafl, a phosphodiesterase type 5 inhibitor, downregulates osteopontin in human peripheral blood mononuclear cells. *Arch. immunol. Ther. Exp.* 65(4), 347-353 (2017).
- <span id="page-9-5"></span>40. Mroczek, T. *et al.* Sildenafl reduces bisphosphonate-induced jaw osteonecrosis in rats. *Clin. Oral Investig.* [https://doi.org/10.1007/](https://doi.org/10.1007/s00784-023-04890-x) [s00784-023-04890-x](https://doi.org/10.1007/s00784-023-04890-x) (2023).
- <span id="page-9-6"></span>41. Kaleta, B., Boguska, A., Borysowski, J. & Gorski, A. Sildenafl upregulates tumor necrosis factor α production in peripheral blood mononuclear cells of healthy men-preliminary report. *Acta Poloniae Pharm. Drug Res.* **76**(1), 123–128 (2019).
- <span id="page-9-7"></span>42. Schulien, I. *et al.* The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating osteopontin expression. *Cell Death Difer.* **26**(9), 1688–1699 (2019).
- <span id="page-9-8"></span>43. Sandner, P. & Stasch, J. P. Anti-fbrotic efects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. *Respir. Med.* **122**, S1–S9 (2017).
- <span id="page-9-9"></span>44. Milenkovic, U., Ilg, M. M., Cellek, S. & Albersen, M. Pathophysiology and future therapeutic perspectives for resolving fibrosis in Peyronie's disease. *Sex. Med. Rev.* **7**(4), 679–689 (2019).
- <span id="page-9-10"></span>45. Wen, Y., Jeong, S., Xia, Q. & Kong, X. Role of osteopontin in liver diseases. *Int. J. Biol. Sci.* **12**(9), 1121 (2016).
- <span id="page-9-11"></span>46. Putra, A. *et al.* Mesenchymal stem cells suppress Tgf-β release to decrease Α-Sma expression in ameliorating Ccl4-induced liver fbrosis. *Res. Sq.* <https://doi.org/10.21203/rs.3.rs-27572/v1> (2020).
- <span id="page-9-12"></span>47. Gharbia, S. *et al.* Adipose-derived stem cells (ADSCs) supplemented with hepatocyte growth factor (HGF) attenuate hepatic stellate cell activation and liver fbrosis by inhibiting the TGF-β/Smad signaling pathway in chemical-induced liver fbrosis associated with diabetes. *Cells* **11**(21), 3338 (2022).
- <span id="page-9-13"></span>48. Xiang, Y. *et al.* sildenafl may have an inhibition efect on the TGFÎ2 1-Smad2/3 pathway in PAH rats. *Biomed. J. Sci. Tech. Res.* **15**(2), 1–6 (2019).
- <span id="page-9-14"></span>49. Balaphas, A. *et al.* Platelet transforming growth factor-β1 induces liver sinusoidal endothelial cells to secrete interleukin-6. *Cells* **9**(5), 1311 (2020).
- <span id="page-9-15"></span>50. Hermansyah, D., Putra, A., Muhar, A. M., Wirastuti, K. & Dirja, B. T. Mesenchymal stem cells suppress TGF-β release to decrease α-SMA expression in ameliorating CCl4-induced liver fbrosis. *Med. Arch.* **75**(1), 16–22 (2021).
- <span id="page-9-16"></span>51. Cardoso-Lezama, I. *et al.* Serum α-SMA is a potential noninvasive biomarker of liver fbrosis. *Toxicol. Mech. Methods* [https://doi.](https://doi.org/10.1080/15376516.2023.2244061) [org/10.1080/15376516.2023.2244061](https://doi.org/10.1080/15376516.2023.2244061) (2023).
- <span id="page-9-17"></span>52. Barghi, M., Ashrafi, M., Aminlari, M., Namazi, F. & Nazifi, S. The protective effect of Zataria multiflora Boiss essential oil on CCl<sub>4</sub> induced liver fbrosis in rats. *Drug Chem. Toxicol.* **44**(3), 229–237 (2021).

# **Acknowledgements**

The authors are grateful to Dr. Samah Ibrahim Hussein and Dr. Sarah Nabil the lecturers of Pathology, Faculty of Medicine, Benha University, Egypt, for their help.

# **Author contributions**

HEN, NOE, RSE, SAE, and LAM designed the study, collected the samples, and applied PCR testing. AMH, HAE, and WBE collected the samples, analyzed the data, and wrote the fnal manuscript. All authors revised and approved the manuscripts. All authors give their consent to publish this article in Scientifc Reports.

# **Funding**

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

# **Competing interests**

The authors declare no competing interests.

# **Additional information**

Supplementary Information The online version contains supplementary material available at [https://doi.org/](https://doi.org/10.1038/s41598-024-67305-1) [10.1038/s41598-024-67305-1](https://doi.org/10.1038/s41598-024-67305-1).

**Correspondence** and requests for materials should be addressed to A.M.H.

**Reprints and permissions information** is available at [www.nature.com/reprints.](www.nature.com/reprints)

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

**Open Access** Tis article is licensed under a Creative Commons Attribution 4.0 International  $\bigcirc$  $\odot$ License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit<http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024